Buti, Maria
Vaz-Pinto, Inês
Magno Pereira, Vítor
Casado, Marta
Llaneras, Jordi
Barreira, Ana
Esteves, Catarina
Guimarães, Mafalda
Gorgulho, Ana
Mourão, Tomás
Xavier, Elisa
Jasmins, Luís
Reis, Ana Paula
Faria, Nancy
Freitas, Bruno
Andrade, Graça
Camelo-Castillo, Anny
Rodríguez-Maresca, Manuel Ángel
Carrodeguas, Alba
Medina, Diogo
Esteban, Rafael
Article History
Received: 4 November 2022
Accepted: 1 December 2023
First Online: 4 January 2024
Declarations
:
: HCV screening and linkage to care are considered standard medical practices according to both Spanish and Portuguese healthcare policies. When enhanced screening and linkage to care practices required modifying consent procedures from written opt-in consent to oral opt-out consent, the formal opinion of the local ethics committee or local public health authorities was requested (Clinical Research Ethics Committee in Vall d’Hebron code PR(AG)86/2020). The study was conducted according to the World Medical Association Declaration of Helsinki.
: Not applicable
: Diogo Medina owns stock in and is an employee of Gilead Sciences. Alba Carrodeguas is an employee of Gilead Sciences. Dr. Buti and Dr. Esteban declare having received honoraria for providing consultancy on advisory board meetings and speaking at symposiums from Gilead Sciences and Abbvie. Dr. Casado received honoraria for lectures and advisory boards from Gilead Sciences, Abbvie, and Intercept. Dr. Vaz Pinto states having received lecture and advisory fees from Gilead, Janssen, and ViiV. Dr. Camelo-Castillo has received travel grants and conference fees from Gilead. Data collection and management were conducted independently, with additional oversight from independent data monitoring agencies. The other authors declare that they have no competing interests.